A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis

Key Points

• No significant difference in effectiveness observed for ocrelizumab and natalizumab in treating multiple sclerosis relapses.
• Effectiveness metrics included relapse risk, disability progression, and MRI activity over the study period.
• Observational analysis using nationwide registry data evaluated treatment impacts on multiple sclerosis outcomes.
• Findings indicate that both treatments may provide similar benefits, warranting further investigation into treatment strategies.